Sign up to save your podcasts
Or
Share Richard Horton on the Oxford vaccine phase 3 trial
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
Richard Horton on the Oxford vaccine phase 3 trial
Editor-in-chief of The Lancet, Richard Horton, discusses the results of the Oxford vaccine's phase 3 trial.
Continue this conversation on social!
Follow us today at...
https://thelancet.bsky.social/
https://instagram.com/thelancetgroup
https://facebook.com/thelancetmedicaljournal
https://linkedIn.com/company/the-lancet
https://youtube.com/thelancettv
View all episodes
By The Lancet GroupEditor-in-chief of The Lancet, Richard Horton, discusses the results of the Oxford vaccine's phase 3 trial.
Continue this conversation on social!
Follow us today at...
https://thelancet.bsky.social/
https://instagram.com/thelancetgroup
https://facebook.com/thelancetmedicaljournal
https://linkedIn.com/company/the-lancet
https://youtube.com/thelancettv
More shows like The Lancet in conversation with
View all
NEJM This Week
320 Listeners
The Daily
112,433 Listeners
GPnotebook Podcast
22 Listeners
The Lancet Voice
22 Listeners
The Lancet Child & Adolescent Health in conversation with
0 Listeners
The Lancet Digital Health in conversation with
0 Listeners
The Lancet Global Health in conversation with
2 Listeners
The Lancet Oncology in conversation with
1 Listeners
The Lancet Psychiatry in conversation with
0 Listeners
The Lancet Respiratory Medicine in conversation with
1 Listeners
The Lancet Haematology in conversation with
0 Listeners
The Lancet Gastroenterology & Hepatology in conversation with
1 Listeners
The Lancet Diabetes & Endocrinology in conversation with
1 Listeners
The Lancet Infectious Diseases in conversation with
0 Listeners
The Lancet Public Health in conversation with
1 Listeners
The Lancet Microbe in conversation with
0 Listeners
eBioMedicine in conversation with
0 Listeners
In conversation with...
0 Listeners
The Lancet Rheumatology in conversation with
0 Listeners
The Lancet Regional Health in conversation with
0 Listeners
The Lancet Primary Care in conversation with
0 Listeners
The Lancet Regional Health Americas in conversation with
0 Listeners